Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma

on behalf of Japanese Urological Oncology Group

doi:10.1016/j.jgo.2020.12.012

Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma

on behalf of Japanese Urological Oncology Group

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	834-837
Number of pages	4
Journal	Journal of Geriatric Oncology
Volume	12
Issue number	5
DOIs	https://doi.org/10.1016/j.jgo.2020.12.012
Publication status	Published - Jun 2021

All Science Journal Classification (ASJC) codes

Oncology
Geriatrics and Gerontology

Access to Document

10.1016/j.jgo.2020.12.012

Cite this

@article{85ad078406aa4f609e1697d2d63f03cf,

title = "Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma",

author = "{on behalf of Japanese Urological Oncology Group} and Yasutomo Nakai and Ario Takeuchi and Takahiro Osawa and Takahiro Kojima and Tomohiko Hara and Mikio Sugimoto and Masatoshi Eto and Keita Minami and Kosuke Ueda and Michinobu Ozawa and Motohide Uemura and Yasuyuki Miyauchi and Kojiro Ohba and Akira Kashiwagi and Masaya Murakami and Tomokazu Sazuka and Hiroaki Yasumoto and Shuichi Morizane and Yoshihide Kawasaki and Daichi Morooka and Toru Shimazui and Yoshiaki Yamamoto and Hiroshi Nakagomi and Ryotaro Tomida and Ito, {Yoichi M.} and Sachiyo Murai and Hiroshi Kitamura and Hiroyuki Nishiyama and Nobuo Shinohara",

note = "Funding Information: Mikio Sugimoto has received honoraria from Astellas, AstraZeneca, Janssen, and Takeda. Masatoshi Eto received honoraria for lectures from ONO, BMS, Pfizer, Novartis, MSD, and Chugai, and for research funding from ONO, Pfizer, Chugai, BMS, Eisai, Bayer and MSD. Akira Yokomizo has received honoraria from Astellas. Takamitsu Inoue reports scholarship endowments from BMS. Hiroyuki Nishiyama has received honoraria from Ono and Chugai; and received research funds from Ono, Takeda, and Astellas; and reports scholarship endowments from MSD, Astellas, AstraZeneca, and Chugai. Nobuo Shinohara has received honoraria from Bayer, Ono, and Astellas; and reports institutional research funding from Ono, Takeda, Sanofi, Taiho, and Astellas. The other authors have no conflicts of interest.",

year = "2021",

month = jun,

doi = "10.1016/j.jgo.2020.12.012",

language = "English",

volume = "12",

pages = "834--837",

journal = "Journal of Geriatric Oncology",

issn = "1879-4068",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma

AU - on behalf of Japanese Urological Oncology Group

AU - Nakai, Yasutomo

AU - Takeuchi, Ario

AU - Osawa, Takahiro

AU - Kojima, Takahiro

AU - Hara, Tomohiko

AU - Sugimoto, Mikio

AU - Eto, Masatoshi

AU - Minami, Keita

AU - Ueda, Kosuke

AU - Ozawa, Michinobu

AU - Uemura, Motohide

AU - Miyauchi, Yasuyuki

AU - Ohba, Kojiro

AU - Kashiwagi, Akira

AU - Murakami, Masaya

AU - Sazuka, Tomokazu

AU - Yasumoto, Hiroaki

AU - Morizane, Shuichi

AU - Kawasaki, Yoshihide

AU - Morooka, Daichi

AU - Shimazui, Toru

AU - Yamamoto, Yoshiaki

AU - Nakagomi, Hiroshi

AU - Tomida, Ryotaro

AU - Ito, Yoichi M.

AU - Murai, Sachiyo

AU - Kitamura, Hiroshi

AU - Nishiyama, Hiroyuki

AU - Shinohara, Nobuo

N1 - Funding Information: Mikio Sugimoto has received honoraria from Astellas, AstraZeneca, Janssen, and Takeda. Masatoshi Eto received honoraria for lectures from ONO, BMS, Pfizer, Novartis, MSD, and Chugai, and for research funding from ONO, Pfizer, Chugai, BMS, Eisai, Bayer and MSD. Akira Yokomizo has received honoraria from Astellas. Takamitsu Inoue reports scholarship endowments from BMS. Hiroyuki Nishiyama has received honoraria from Ono and Chugai; and received research funds from Ono, Takeda, and Astellas; and reports scholarship endowments from MSD, Astellas, AstraZeneca, and Chugai. Nobuo Shinohara has received honoraria from Bayer, Ono, and Astellas; and reports institutional research funding from Ono, Takeda, Sanofi, Taiho, and Astellas. The other authors have no conflicts of interest.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85099691432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099691432&partnerID=8YFLogxK

U2 - 10.1016/j.jgo.2020.12.012

DO - 10.1016/j.jgo.2020.12.012

M3 - Letter

C2 - 33388281

AN - SCOPUS:85099691432

SN - 1879-4068

VL - 12

SP - 834

EP - 837

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

IS - 5

ER -

Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this